Maintenance immunotherapy in recurrent ovarian cancer: Long term follow-up of a phase II study

Gynecologic Oncology

Volumn 116, Issue 2, 2010, Pages 202-207

  Recchia, Francesco ^a,b   Di Orio, Ferdinando ^c   Candeloro, Giampiero ^a   Guerriero, Gabriele ^b   Piazze, Juan ^b   Rea, Silvio ^b,c  

^a Ospedale Civile di Avezzano   (Italy)

^b Fondazione Carlo Ferri   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

13 cis retinoic acid; Advanced ovarian cancer; Interleukin 2; Maintenance immunotherapy

Indexed keywords

INTERLEUKIN 2; ISOTRETINOIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ERYTHEMA NODOSUM; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPOTHYROIDISM; IMMUNOTHERAPY; LONG TERM CARE; LOW DRUG DOSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; OVARY CANCER; PERICARDIAL EFFUSION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; ISOTRETINOIN; KILLER CELLS, NATURAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; T-LYMPHOCYTES, REGULATORY; TAXOIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 73949118563     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.09.042     Document Type: Article

References (42)

1. American Cancer Society. Cancer Facts & Figures 2008 (2008), American Cancer Society, Atlanta
2. Bukowski R.M., Ozols R.F., and Markman M. The management of recurrent ovarian cancer. Semin. Oncol. 34 2 Suppl 2 (2007) S1-15
3. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
4. Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96 (2004) 1682-1691
5. Mathe G., and Reizenstein P. Managing minimal residual malignant disease. Oncology 43 (1986) 137-142
6. Baba T., Convery P.A., Matsumura N., Whitaker R.S., Kondoh E., Perry T., et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 28 (2009) 209-218
7. Zhang S., Balch C., Chan M.W., Lai H.C., Matei D., Schilder J.M., et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68 (2008) 4311-4320
8. Möbus V., Wandt H., Frickhofen N., Bengala C., Champion K., Kimmig R., et al. AGO-Ovar/AIO; EBMT. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J. Clin. Oncol. 25 (2007) 4157-4158
9. Markman M., Liu P.Y., Wilczynski S., Monk B., Copeland L.J., Alvarez R.D., et al. Phase III randomised study of 12 versus three months of single-agent paclitaxel in patients with advanced ovarian cancer who attained a clinically defined complete response to a platinum/paclitaxel-based chemotherapy: a southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol. 21 (2003) 2460-2465
10. Ohm J.E., and Carbone D.P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res. 23 (2001) 263-272
11. Alvarez Secord A., Sayer R., Snyder S.A., Broadwater G., Rodriguez G.C., Berchuck A., et al. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. Gynecol. Oncol. 94 (2004) 74-79
12. Berek J., Taylor P., McGuire W., Smith L.M., Schultes B., and Nicodemus C.F. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J. Clin. Oncol. 27 (2009) 418-425
13. Dadmarz R.D., Ordoubadi A., Mixon A., Thompson C.O., Barracchini K.C., Hijazi Y.M., et al. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. Cancer J. Sci. Am. 5 (1996) 263-272
14. Santin A.D., Bellone S., Ravaggi A., Pecorelli S., Cannon M.J., and Parham G.P. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet. Gynecol. 96 (2000) 422-430
15. Smith K.A. Interleukin-2: inception, impact and implications. Science 240 (1988) 1169-1176
16. Prabhala R.H., Garenwal H.S.S., Hicks M.J., Sampliner R.E., and Watson R.R. The effects of 13-cis-Retinoic acid and beta-carotene on cellular immunity in humans. Cancer 67 (1991) 1556-1560
17. Keane M.P., Belperio J.A., Arenberg D.A., et al. IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J. Immunol. 163 (1999) 5686-5692
18. Recchia F., De Filippis S., Rosselli M., Saggio G., Cesta A., Fumagalli L., et al. Phase IB study of subcutaneously administered Interleukin-2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer. Clin. Cancer Res. 7 (2001) 1251-1257
19. Recchia F., Saggio G., Cesta A., Candeloro G., Nuzzo A., Lombardo M., et al. Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer. Int. J. Oncol. 27 (2005) 1039-1046
20. Recchia F., De Filippis S., Saggio G., Amiconi G., Cesta A., Carta G., et al. Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer. Anticancer Drugs 14 (2003) 633-638
21. Recchia F., Saggio G., Amiconi G., Di Blasio A., Cesta A., Candeloro, et al. A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer. Gynecol. Oncol. 106 (2007) 164-169
22. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guide lines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
23. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9 (1991) 389-393
24. Recchia F., Saggio G., Cesta A., Alesse E., Gallo R., Necozione S., et al. Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy. Anticancer Res. 25 (2005) 3149-3157
25. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials 10 (1989) 1-10
26. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Ass. 53 (1958) 457-481
27. Bamias A., Koutsoukou V., Terpos E., Tsiatas M.L., Liakos C., Tsitsilonis O., et al. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol. Oncol. 108 (2008) 421-427
28. Scholz C., Rampf E., Toth B., Brunnhuber R., Weissenbacher T., Friese K., et al. Ovarian cancer-derived glycodelin impairs in vitro dendritic cell maturation. J. Immunother. 32 (2009) 492-497
29. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, Xuorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
30. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357 (2007) 2666-2676
31. Burger R.A., Sill M.W., Monk B.J., Greer B.E., and Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer. J. Clin. Oncol. 25 (2007) 5165-5171
32. Cannistra S.A., Matulonis U.A., Penson R.T., Hambleton J., Dupont J., Mackey H., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25 (2007) 5180-5186
33. Disis M.L., and Kim Lyerly K. Global role of the immune system in identifying cancer initiation and limiting disease progression. J. Clin. Oncol. 23 (2005) 8923-8925
34. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004) 531-562
35. Cesana G.C., DeRaffele G., Cohen S., Moroziewicz D., Mitcham J., Stoutenburg J., et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 24 (2006) 1169-1177
36. Keane M.P., Belperio J.A., Arenberg D.A., Burdick M.D., Xu Z.J., Xue Y.Y., et al. IFN-gammainducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J. Immunol. 163 (1999) 5686-5692
37. Recchia F., Sica G., Candeloro G., Necozione S., Bisegna R., Bratta M., et al. Maintenance immunotherapy in metastatic breast cancer. Oncol. Rep. 20 (2008) 1173-1179
38. Recchia F., Candeloro G., Di Staso M., Necozione S., Bisegna R., Bratta M., et al. Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Immunother. 31 (2008) 413-419
39. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., et al. Gr-1+CD115+immature myeloid suppressor cells mediate the development of tumorinduced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66 (2006) 1123-1131
40. Kusmartsev S., Cheng F., Yu B., Nefedova Y., Sotomayor E., Lush R., et al. All trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63 (2003) 4441-4449
41. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 (2003) 252-254
42. Oikawa T., Hirotani K., Nakamura O., Shudo K., Hiragun A., and Iwaguchi T. A highly potent antiangiogenic activity of retinoids. Cancer Lett. 48 (1989) 157-162